Brief: Moshe Arkin Initially Bought Eiger Biopharmaceuticals Securities Believing Those Were Undervalued & Had Attractive Investment Opportunity

Eiger Biopharmaceuticals

24/11/2023 12:12

Nov 24 (Reuters) - Eiger BioPharmaceuticals Inc
 EIGR.O :
    * MOSHE ARKIN INITIALLY BOUGHT EIGER BIOPHARMACEUTICALS
SECURITIES
BELIEVING THOSE WERE UNDERVALUED & HAD ATTRACTIVE INVESTMENT
OPPORTUNITY- SEC FILING
    * MOSHE ARKIN ON NOV 14 ISSUED EIGER BOARD A LETTER
SUBSTANTIALLY
STATING THAT EIGER SHOULD FILE A NEW DRUG APPLICATION FOR
LONAFARNIB - SEC FILING
    * MOSHE ARKIN'S LETTER ALSO STATED THAT EIGER SHOULD FINANCE
LONAFARNIB DEVELOPMENT VIA PRIVATE OFFERING WITH EIGER'S MAJOR
SHAREHOLDERS - SEC FILING
    * MOSHE ARKIN'S LETTER ALSO STATED IT DOES NOT BELIEVE
ALLOCATING
RESOURCES TO DEVELOPMENT OF LONAFARNIB WILL COME AT EXPENSE OF
AVEXITIDE
    * MOSHE ARKIN HOLDS 10.09% OF EIGER BIOPHARMACEUTICALS INC
SHARES
AS AT NOV 14

Further company coverage:  EIGR.O 

 ((Reuters.Briefs@thomsonreuters.com;))